Genzyme General News

Recently, we posted about misadventures of the leadership of biotechnology giant Genzyme.

Shares of AMD now seen reaching $9. Estimates also boosted, as the debt recapitalization will pay off.

Following a five-week inspection of Genzyme's plant in Allston Landing, MA, the US Food and Drug Administration is still not satisfied with the company's large-scale manufacturing of Lumizyme.

Genzyme Corp , which is struggling through the most trying period in its history, said on Monday U.S. regulators will not approve its drug to treat Pompe disease, a rare muscle disorder, until it addresses manufacturing deficiencies at its Allston Landing plant in Boston.

Genzyme Corp. said Wednesday it is canceling development of a successor to its kidney treatment Renvela, as the new drug did not work much better than Renvela.

Genzyme Corporation's problems continue with the company recently announcing the discontinuation of the development of its kidney disease drug.

Main Category: GastroIntestinal / Gastroenterology Also Included In: Clinical Trials / Drug Trials Article Date: 20 Nov 2009 Genzyme Corporation reported results of a phase 2/3 study of its advanced phosphate binder .

The problem with a train wreck isn't the first car that goes off the track, but all the ones farther back that come crashing along behind it.

Genzyme Corp. is dropping further work on its advanced phosphate binder - the product expected to save the Cambridge, Mass.-based firm's renal franchise from the looming patent cliff - after it failed to show improvement over Renvela in a Phase II/III trial, leaving analysts and investors to wonder what's next for the big biotech, which has ...

In June, 2009, an article in the Boston Globe described how the Boston area based biotechnology company Genzyme sold some astonishlingly expensive drugs, using a remarkable business strategy : In countries from Colombia to Taiwan to Libya, the Cambridge firm has compiled an extraordinary track record of searching out patients like Tania, providing ...

An experimental drug from Isis Pharmaceuticals and Genzyme cut levels of "bad" LDL cholesterol by 25% in patients with a rare genetic disorder that causes extremely high and dangerous levels of cholesterol, according to data presented today at a medical meeting.

Genzyme Corporation today reported results of a phase 2/3 study of its advanced phosphate binder .

The winner of the 2009 Worst Biotech CEO of the Year Award goes to Genzyme's Henri Termeer.

An experimental drug for patients genetically disposed to extreme high cholesterol being developed by Isis Pharmaceuticals Inc and Genzyme Corp significantly lowered cholesterol in a pivotal late-stage study, according to data presented on Tuesday.

The affected drugs include Cerezyme, Myozyme, Fabrazyme, Aldurazyme and Thyrogen.

The Food and Drug Administration has said it will not approve Genzymea s new drug, Lumizyme, until contamination of vials at the companya s Allston facility is fixed.A The drug is used to treat Pompe disease.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/13/09, Celgene Corporation announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of ...

Cambridge, MA. is ranked the top city for commuters to live in. In a new report published this week by US News and World Report and featured on Yahoo Real Estate , it was said: Cambridge, Mass.

Smith Micro Software Inc. said Wednesday it turned a profit in the third quarter but cut its 2009 revenue estimate, sending shares tumbling nearly 20 percent in aftermarket trading.

The U.S. Food and Drug Administration said the particles found in vials of the drugs - stainless steel fragments, non-latex rubber from vial stoppers and fiber-like material from the manufacturing process - could cause serious adverse health effects in patients.